Literature DB >> 21537479

Isolation and optimization of camelid single-domain antibodies: Dirk Saerens' work on nanobodies.

Dirk Saerens1.   

Abstract

It is well established that all camelids have unique antibodies circulating in their blood. Unlike antibodies from all other species, these special antibodies are devoid of light chains, and are composed of a heavy chain homodimer. These so-called heavy-chain antibodies (HCAbs) are expressed after a V-D-J rearrangement and require dedicated constant gamma genes. An immune response is raised in these HCAbs following a classical immunization protocol. These HCAbs are easily purified from serum, and their antigen-binding fragment interacts with parts of the target that are less antigenic to conventional antibodies. The antigen binding site of the dromedary HCAb comprises one single domain, referred to as VHH or nanobody (Nb), therefore, a strategy was designed to clone the Nb repertoire of an immunized dromedary and to select the Nb with specificity for our target antigens. The monoclonal Nb is produced well in bacteria, is very stable and highly soluble, and it binds the antigen with high affinity and specificity. Currently, the recombinant Nb has been developed successfully for research purposes, as a probe in biosensors, to diagnose infections, or to treat diseases such as cancer or trypanosomiasis.

Entities:  

Keywords:  Heavy-chain antibody; Monoclonal antibody; Nanobody; Single-domain antibody

Year:  2010        PMID: 21537479      PMCID: PMC3083966          DOI: 10.4331/wjbc.v1.i7.235

Source DB:  PubMed          Journal:  World J Biol Chem        ISSN: 1949-8454


  18 in total

1.  Parallel selection of multiple anti-infectome Nanobodies without access to purified antigens.

Authors:  Dirk Saerens; Benoît Stijlemans; Toya Nath Baral; Giang Thanh Nguyen Thi; Ulrich Wernery; Stefan Magez; Patrick De Baetselier; Serge Muyldermans; Katja Conrath
Journal:  J Immunol Methods       Date:  2007-10-31       Impact factor: 2.303

2.  Camelid immunoglobulins and nanobody technology.

Authors:  S Muyldermans; T N Baral; V Cortez Retamozzo; P De Baetselier; E De Genst; J Kinne; H Leonhardt; S Magez; V K Nguyen; H Revets; U Rothbauer; B Stijlemans; S Tillib; U Wernery; L Wyns; Gh Hassanzadeh-Ghassabeh; D Saerens
Journal:  Vet Immunol Immunopathol       Date:  2008-10-17       Impact factor: 2.046

Review 3.  Single-domain antibodies as building blocks for novel therapeutics.

Authors:  Dirk Saerens; Gholamreza Hassanzadeh Ghassabeh; Serge Muyldermans
Journal:  Curr Opin Pharmacol       Date:  2008-08-22       Impact factor: 5.547

4.  General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold.

Authors:  Cécile Vincke; Remy Loris; Dirk Saerens; Sergio Martinez-Rodriguez; Serge Muyldermans; Katja Conrath
Journal:  J Biol Chem       Date:  2008-11-14       Impact factor: 5.157

Review 5.  Antibody technology in proteomics.

Authors:  Dirk Saerens; Gholamreza Hassanzadeh Ghassabeh; Serge Muyldermans
Journal:  Brief Funct Genomic Proteomic       Date:  2008-06-27

6.  Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies.

Authors:  Dirk Saerens; Mireille Pellis; Remy Loris; Els Pardon; Mireille Dumoulin; André Matagne; Lode Wyns; Serge Muyldermans; Katja Conrath
Journal:  J Mol Biol       Date:  2005-09-23       Impact factor: 5.469

7.  A bispecific nanobody to provide full protection against lethal scorpion envenoming.

Authors:  Issam Hmila; Dirk Saerens; Rahma Ben Abderrazek; Cécile Vincke; Naima Abidi; Zakaria Benlasfar; Jochen Govaert; Mohamed El Ayeb; Balkiss Bouhaouala-Zahar; Serge Muyldermans
Journal:  FASEB J       Date:  2010-04-21       Impact factor: 5.191

8.  An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology.

Authors:  Magdalena Pleschberger; Dirk Saerens; Stefan Weigert; Uwe B Sleytr; Serge Muyldermans; Margit Sára; Eva M Egelseer
Journal:  Bioconjug Chem       Date:  2004 May-Jun       Impact factor: 4.774

9.  Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains.

Authors:  Dirk Saerens; Katja Conrath; Jochen Govaert; Serge Muyldermans
Journal:  J Mol Biol       Date:  2008-01-16       Impact factor: 5.469

10.  Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils.

Authors:  Pak-Ho Chan; Els Pardon; Linda Menzer; Erwin De Genst; Janet R Kumita; John Christodoulou; Dirk Saerens; Alain Brans; Fabrice Bouillenne; David B Archer; Carol V Robinson; Serge Muyldermans; André Matagne; Christina Redfield; Lode Wyns; Christopher M Dobson; Mireille Dumoulin
Journal:  Biochemistry       Date:  2008-09-25       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.